HomeCompareCGUI vs PFE

CGUI vs PFE: Dividend Comparison 2026

CGUI yields 4.00% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $25.1K in total portfolio value· pulled ahead in Year 9
10 years
CGUI
CGUI
● Live price
4.00%
Share price
$25.28
Annual div
$1.01
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.9K
Annual income
$516.95
Full CGUI calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — CGUI vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCGUIPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CGUI + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CGUI pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CGUI
Annual income on $10K today (after 15% tax)
$339.92/yr
After 10yr DRIP, annual income (after tax)
$439.41/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, PFE beats the other by $22,689.55/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CGUI + PFE for your $10,000?

CGUI: 50%PFE: 50%
100% PFE50/50100% CGUI
Portfolio after 10yr
$38.5K
Annual income
$13,863.75/yr
Blended yield
36.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

CGUI
No analyst data
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CGUI buys
0
PFE buys
0
No recent congressional trades found for CGUI or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCGUIPFE
Forward yield4.00%6.20%
Annual dividend / share$1.01$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$25.9K$51.1K
Annual income after 10y$516.95$27,210.54
Total dividends collected$4.6K$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CGUI vs PFE ($10,000, DRIP)

YearCGUI PortfolioCGUI Income/yrPFE PortfolioPFE Income/yrGap
1$11,100$399.90$9,161$701.38+$1.9KCGUI
2$12,292$414.85$8,610$859.79+$3.7KCGUI
3$13,581$429.34$8,366$1,081.25+$5.2KCGUI
4$14,976$443.35$8,483$1,405.66+$6.5KCGUI
5$16,481$456.88$9,084$1,907.24+$7.4KCGUI
6$18,104$469.90$10,418$2,732.78+$7.7KCGUI
7$19,854$482.43$13,007$4,193.56+$6.8KCGUI
8$21,738$494.44$18,010$7,005.87+$3.7KCGUI
9← crossover$23,766$505.95$28,216$12,979.89$4.5KPFE
10$25,946$516.95$51,081$27,210.54$25.1KPFE

CGUI vs PFE: Complete Analysis 2026

CGUIStock

To provide current income consistent with an ultra-short duration profile, focused on preservation of capital.Distinguishing Characteristics The fund invests primarily in U.S. dollar denominated, investment-grade, short-term debt, including short-term money market instruments such as commercial paper and certificates of deposit, U.S. government bonds, corporate securities and asset-backed securities. The fund will normally invest more than 25% of its assets in securities issued by companies in the financials group of industries. The fund may invest substantially in debt securities that are tied economically to countries outside the United States, including securities issued by foreign corporations or foreign governments and their agencies and instrumentalities. The fund may also invest in futures contracts and swaps, which are types of derivatives. A derivative is a financial contract, the value of which is based on the value of an underlying financial asset (such as a stock, bond or currency), a reference rate or a market index.The fund will invest at least 80% of its assets in bonds and other debt securities that accrue income, which may be represented by derivatives. The fund consists primarily of investment-grade debt with a minimum short-term rating of P-2, A-2, F2, or a minimum long-term rating of BBB- or Baa3, in each case given by the Nationally Recognized Statistical Rating Organizations designated by the fund’s investment adviser or unrated but determined to be of equivalent quality by the fund’s investment adviser. The fund may invest up to 5% in debt securities rated BB+ or Ba1 or below, but with a minimum rating of BB- (or Ba3). The fund normally seeks to maintain an average portfolio duration of one year or less, and a dollar-weighted average maturity of two years or less. The fund will normally invest more than 25% of its assets in securities issued by companies in the financials group of industries.

Full CGUI Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this CGUI vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CGUI vs SCHDCGUI vs JEPICGUI vs OCGUI vs KOCGUI vs MAINCGUI vs JNJCGUI vs MRKCGUI vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.